Aethlon Medical Inc (AEMD)

[My 2 Cents]

http://www.hcvadvocate.org/hcsp/articles/current_standards_2006.html


AEMD is about to throw a curveball at whoever wrote this article :)


"Tomorrow’s Standard of Care?
Currently, there are new therapeutic approaches being investigated in an effort to augment SVR rates in all patient groups, especially those who currently have a poor response to therapy. Several novel IFNs, interferon delivery systems, IRES inhibitors, ribavirin-like molecules, protease and polymerase inhibitors, newer immunomodulators, and other hepatitis C replication enzyme inhibitors are currently being studied in clinical trials. In addition, antifibrotic agents, caspase inhibitors and antibody therapies and vaccines are also under development."